middle.news
Clarity Pharmaceuticals Advances Breast Cancer Pipeline with Cu-64/67 SAR-Trastuzumab
8:57am on Monday 2nd of June, 2025 AEST
•
Pharmaceuticals
Read Story
Clarity Pharmaceuticals Advances Breast Cancer Pipeline with Cu-64/67 SAR-Trastuzumab
8:57am on Monday 2nd of June, 2025 AEST
Key Points
Introduction of 64/67Cu-SAR-trastuzumab into Clarity’s Targeted Copper Theranostic portfolio
Pre-clinical data shows significant tumour reduction and survival benefits in HER2-positive models
Supply agreement secured with EirGenix for clinical-grade trastuzumab biosimilar
Plans for Phase 1/2a theranostic clinical trial targeting aggressive HER2-positive breast cancer
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
CU6
OPEN ARTICLE